Cargando…

Conversion Chemotherapy With a Modified FLOX Regimen for Borderline or Unresectable Liver Metastases From Colorectal Cancer: An Alternative for Limited-Resources Settings

PURPOSE: Conversion chemotherapy is often used for borderline or unresectable (B/U) liver metastases from colorectal cancer (CRC) with the aim of achieving resectability. Although intensive and costly regimens are often used, the best regimen in this scenario remains unclear. We aimed to evaluate th...

Descripción completa

Detalles Bibliográficos
Autores principales: Bonadio, Renata Colombo, Amor Divino, Paulo Henrique, Obando, Jorge Santiago Madero, Lima, Karolina Cayres Alvino, Recchimuzzi, Débora Zachello, Kruger, Jaime Arthur Pirola, Saragiotto, Daniel Fernandes, Capareli, Fernanda C., Hoff, Paulo M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6733184/
https://www.ncbi.nlm.nih.gov/pubmed/31479339
http://dx.doi.org/10.1200/JGO.19.00180
_version_ 1783449937843847168
author Bonadio, Renata Colombo
Amor Divino, Paulo Henrique
Obando, Jorge Santiago Madero
Lima, Karolina Cayres Alvino
Recchimuzzi, Débora Zachello
Kruger, Jaime Arthur Pirola
Saragiotto, Daniel Fernandes
Capareli, Fernanda C.
Hoff, Paulo M.
author_facet Bonadio, Renata Colombo
Amor Divino, Paulo Henrique
Obando, Jorge Santiago Madero
Lima, Karolina Cayres Alvino
Recchimuzzi, Débora Zachello
Kruger, Jaime Arthur Pirola
Saragiotto, Daniel Fernandes
Capareli, Fernanda C.
Hoff, Paulo M.
author_sort Bonadio, Renata Colombo
collection PubMed
description PURPOSE: Conversion chemotherapy is often used for borderline or unresectable (B/U) liver metastases from colorectal cancer (CRC) with the aim of achieving resectability. Although intensive and costly regimens are often used, the best regimen in this scenario remains unclear. We aimed to evaluate the outcomes of patients with B/U liver metastases from CRC treated with conversion chemotherapy with the modified fluorouracil, leucovorin, and oxaliplatin (mFLOX) regimen followed by metastasectomy. METHODS: We performed a single-center retrospective analysis of patients with B/U liver metastases from CRC treated with chemotherapy with the mFLOX regimen followed by surgery. B/U disease was defined as at least one of the following: more than four lesions, involvement of hepatic artery or portal vein, or involvement of biliary structure. RESULTS: Fifty-four consecutive patients who met our criteria for B/U liver metastases were evaluated. Thirty-five patients (64%) had more than four liver lesions, 16 (29%) had key vascular structure involvement, and 16 (29%) had biliary involvement. After chemotherapy, all patients had surgery and 42 (77%) had R0 resection. After a median follow-up of 37.2 months, median progression-free survival (PFS) was 16.9 months and median overall survival (OS) was 68.3 months. R1-R2 resections were associated with worse PFS and OS compared with R0 resection (PFS: hazard ratio, 2.65; P = .007; OS: hazard ratio, 2.90; P = .014). CONCLUSION: Treatment of B/U liver metastases from CRC with conversion chemotherapy using mFLOX regimen followed by surgical resection was associated with a high R0 resection rate and favorable survival outcomes. On the basis of our results, we consider mFLOX a low-cost option for conversion chemotherapy among other options that have been proposed.
format Online
Article
Text
id pubmed-6733184
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher American Society of Clinical Oncology
record_format MEDLINE/PubMed
spelling pubmed-67331842019-10-03 Conversion Chemotherapy With a Modified FLOX Regimen for Borderline or Unresectable Liver Metastases From Colorectal Cancer: An Alternative for Limited-Resources Settings Bonadio, Renata Colombo Amor Divino, Paulo Henrique Obando, Jorge Santiago Madero Lima, Karolina Cayres Alvino Recchimuzzi, Débora Zachello Kruger, Jaime Arthur Pirola Saragiotto, Daniel Fernandes Capareli, Fernanda C. Hoff, Paulo M. J Glob Oncol Original Report PURPOSE: Conversion chemotherapy is often used for borderline or unresectable (B/U) liver metastases from colorectal cancer (CRC) with the aim of achieving resectability. Although intensive and costly regimens are often used, the best regimen in this scenario remains unclear. We aimed to evaluate the outcomes of patients with B/U liver metastases from CRC treated with conversion chemotherapy with the modified fluorouracil, leucovorin, and oxaliplatin (mFLOX) regimen followed by metastasectomy. METHODS: We performed a single-center retrospective analysis of patients with B/U liver metastases from CRC treated with chemotherapy with the mFLOX regimen followed by surgery. B/U disease was defined as at least one of the following: more than four lesions, involvement of hepatic artery or portal vein, or involvement of biliary structure. RESULTS: Fifty-four consecutive patients who met our criteria for B/U liver metastases were evaluated. Thirty-five patients (64%) had more than four liver lesions, 16 (29%) had key vascular structure involvement, and 16 (29%) had biliary involvement. After chemotherapy, all patients had surgery and 42 (77%) had R0 resection. After a median follow-up of 37.2 months, median progression-free survival (PFS) was 16.9 months and median overall survival (OS) was 68.3 months. R1-R2 resections were associated with worse PFS and OS compared with R0 resection (PFS: hazard ratio, 2.65; P = .007; OS: hazard ratio, 2.90; P = .014). CONCLUSION: Treatment of B/U liver metastases from CRC with conversion chemotherapy using mFLOX regimen followed by surgical resection was associated with a high R0 resection rate and favorable survival outcomes. On the basis of our results, we consider mFLOX a low-cost option for conversion chemotherapy among other options that have been proposed. American Society of Clinical Oncology 2019-09-03 /pmc/articles/PMC6733184/ /pubmed/31479339 http://dx.doi.org/10.1200/JGO.19.00180 Text en © 2019 by American Society of Clinical Oncology https://creativecommons.org/licenses/by/4.0/ Licensed under the Creative Commons Attribution 4.0 License: https://creativecommons.org/licenses/by/4.0/
spellingShingle Original Report
Bonadio, Renata Colombo
Amor Divino, Paulo Henrique
Obando, Jorge Santiago Madero
Lima, Karolina Cayres Alvino
Recchimuzzi, Débora Zachello
Kruger, Jaime Arthur Pirola
Saragiotto, Daniel Fernandes
Capareli, Fernanda C.
Hoff, Paulo M.
Conversion Chemotherapy With a Modified FLOX Regimen for Borderline or Unresectable Liver Metastases From Colorectal Cancer: An Alternative for Limited-Resources Settings
title Conversion Chemotherapy With a Modified FLOX Regimen for Borderline or Unresectable Liver Metastases From Colorectal Cancer: An Alternative for Limited-Resources Settings
title_full Conversion Chemotherapy With a Modified FLOX Regimen for Borderline or Unresectable Liver Metastases From Colorectal Cancer: An Alternative for Limited-Resources Settings
title_fullStr Conversion Chemotherapy With a Modified FLOX Regimen for Borderline or Unresectable Liver Metastases From Colorectal Cancer: An Alternative for Limited-Resources Settings
title_full_unstemmed Conversion Chemotherapy With a Modified FLOX Regimen for Borderline or Unresectable Liver Metastases From Colorectal Cancer: An Alternative for Limited-Resources Settings
title_short Conversion Chemotherapy With a Modified FLOX Regimen for Borderline or Unresectable Liver Metastases From Colorectal Cancer: An Alternative for Limited-Resources Settings
title_sort conversion chemotherapy with a modified flox regimen for borderline or unresectable liver metastases from colorectal cancer: an alternative for limited-resources settings
topic Original Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6733184/
https://www.ncbi.nlm.nih.gov/pubmed/31479339
http://dx.doi.org/10.1200/JGO.19.00180
work_keys_str_mv AT bonadiorenatacolombo conversionchemotherapywithamodifiedfloxregimenforborderlineorunresectablelivermetastasesfromcolorectalcanceranalternativeforlimitedresourcessettings
AT amordivinopaulohenrique conversionchemotherapywithamodifiedfloxregimenforborderlineorunresectablelivermetastasesfromcolorectalcanceranalternativeforlimitedresourcessettings
AT obandojorgesantiagomadero conversionchemotherapywithamodifiedfloxregimenforborderlineorunresectablelivermetastasesfromcolorectalcanceranalternativeforlimitedresourcessettings
AT limakarolinacayresalvino conversionchemotherapywithamodifiedfloxregimenforborderlineorunresectablelivermetastasesfromcolorectalcanceranalternativeforlimitedresourcessettings
AT recchimuzzideborazachello conversionchemotherapywithamodifiedfloxregimenforborderlineorunresectablelivermetastasesfromcolorectalcanceranalternativeforlimitedresourcessettings
AT krugerjaimearthurpirola conversionchemotherapywithamodifiedfloxregimenforborderlineorunresectablelivermetastasesfromcolorectalcanceranalternativeforlimitedresourcessettings
AT saragiottodanielfernandes conversionchemotherapywithamodifiedfloxregimenforborderlineorunresectablelivermetastasesfromcolorectalcanceranalternativeforlimitedresourcessettings
AT caparelifernandac conversionchemotherapywithamodifiedfloxregimenforborderlineorunresectablelivermetastasesfromcolorectalcanceranalternativeforlimitedresourcessettings
AT hoffpaulom conversionchemotherapywithamodifiedfloxregimenforborderlineorunresectablelivermetastasesfromcolorectalcanceranalternativeforlimitedresourcessettings